Home NDC 45629-134-02 FOTIVDA
Product NDC 45629-134
Requested package NDC 45629-134-02
11-digit product format 456290134
Labeler code 45629
Product ID 45629-134_c9661f6f-3568-4df6-bb6c-a461f9ae6e14
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Tivozanib
Dosage form CAPSULE
Route ORAL
Labeler AVEO Pharmaceuticals, Inc.
Application NDA212904
Marketing category NDA
Marketing start 2021-03-10
Substance TIVOZANIB HYDROCHLORIDE
Active strength 1.34 mg/1
Pharmacologic classes Kinase Inhibitor [EPC], Tyrosine Kinase Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N212904-001 FOTIVDA TIVOZANIB HYDROCHLORIDE EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 N212904-002 FOTIVDA TIVOZANIB HYDROCHLORIDE EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10
Orange Book patents# Current patent rows page 1 of 1 · 6 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 N212904-001 12778944 2039-11-05 U-4640 2026-11-10 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 N212904-002 12778944 2039-11-05 U-4640 2026-11-10
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N212904-001 NCE 2026-03-10 N212904-002 NCE 2026-03-10
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 76 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 c2088c7a36db…2026-09-14 22:38:34 2026-08 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 84e616aacf4f…2026-08-18 06:07:40 2026-07 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N212904-001 FOTIVDA EQ 0.89MG BASE CAPSULE / ORAL RLD 2021-03-10 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N212904-002 FOTIVDA EQ 1.34MG BASE CAPSULE / ORAL RLD, RS 2021-03-10 5d02ea3f76ae…
Observed Orange Book patent history# Patent history page 1 of 5 · 196 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-001 12778944 2039-11-05 U-4640 2026-11-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212904-002 12778944 2039-11-05 U-4640 2026-11-10 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 c2088c7a36db…2026-09-14 22:38:34 2026-08 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 84e616aacf4f…2026-08-18 06:07:40 2026-07 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-001 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-002 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N212904-001 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-002 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-001 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-001 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-001 11504365 2039-11-05 U-3476 2022-12-01 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-002 6821987 2025-04-26 U-3100 Drug substance, Drug product 2021-04-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-002 7166722 2028-11-16 Drug substance, Drug product 2021-04-06 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N212904-002 11504365 2039-11-05 U-3476 2022-12-01 fd3edfee7708…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 74 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base FOTIVDA
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength TIVOZANIB HYDROCHLORIDE 1.34 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 8A9H4VK35Z Internal UNII lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# Effective, Related label table Effective Related label 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-08-14 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2025-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-08-25 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021 2022-07-29 These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. FOTIVDA ® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 45629-134-01 FOTIVDA 21 in 1 BOTTLE, PLASTIC CAPSULE 21 13 45629-134-01 FOTIVDA 1 in 1 BAG CAPSULE 1 13 45629-134-02 FOTIVDA 21 in 1 BOTTLE, PLASTIC CAPSULE 21 13 45629-134-02 FOTIVDA 1 in 1 CARTON CAPSULE 1 13
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 45629-134 FOTIVDA (TIVOZANIB) CAPSULE [AVEO PHARMACEUTICALS, INC.] 7 Current NDC, Legacy NDC, 4 package rows 20250524_de77155c-ecf2-4f15-9758-21d271449d83.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Sample Exclude flag Status 45629-134-02 45629013402 1 BOTTLE, PLASTIC in 1 CARTON (45629-134-02) / 21 CAPSULE in 1 BOTTLE, PLASTIC 2025-01-30 No No Current